An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy.

Lach-Trifilieff, Estelle; Minetti, Giulia C; Sheppard, KellyAnn; Ibebunjo, Chikwendu; Feige, Jerome N; Hartmann, Steffen; Brachat, Sophie; Rivet, Helene; Koelbing, Claudia; Morvan, Frederic; Hatakeyama, Shinji; Glass, David J

Lach-Trifilieff, Estelle; Minetti, Giulia C; Sheppard, KellyAnn; Ibebunjo, Chikwendu; Feige, Jerome N; Hartmann, Steffen; Brachat, Sophie; Rivet, Helene; Koelbing, Claudia; Morvan, Frederic; Hatakeyama, Shinji; Glass, David J.

Affiliation

Lach-Trifilieff E; MusculoSkeletal Diseases, Novartis Institutes for Biomedical Research, Basel, Switzerland.

Mol Cell Biol ; 34(4): 606-18, 2014 Feb.

Article in En | MEDLINE | ID: mdl-24298022

Subject(s)

Activin Receptors, Type II/immunology; Activins/metabolism; Antibodies, Blocking/pharmacology; Antibodies, Monoclonal/pharmacology; Hypertrophy/metabolism; Myoblasts, Skeletal/metabolism; Activin Receptors, Type II/metabolism; Animals; Antibodies, Blocking/metabolism; Antibodies, Monoclonal/metabolism; Antibodies, Monoclonal, Humanized; Atrophy/immunology; Atrophy/metabolism; Cell Differentiation/physiology; Humans; Hypertrophy/pathology; Mice; Muscle, Skeletal/metabolism; Muscle, Skeletal/pathology; Myoblasts, Skeletal/immunology; Signal Transduction/physiology; Smad2 Protein/metabolism; Smad3 Protein/metabolism

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Antibodies, Blocking / Activins / Activin Receptors, Type II / Myoblasts, Skeletal / Hypertrophy / Antibodies, Monoclonal Limits: Animals / Humans Language: En Year: 2014 Type: Article

Fulltext

XML

PubMed Links

Search on Google